High-flow nasal cannula (HFNC) is a rather novel system to provide oxygen therapy, which provides flows up to 60 liters/minute (LPM) of heated and humidified gas through nasal prongs. HFNC is increasingly being used in patients with acute respiratory failure. In healthy volunteers and in patients with acute respiratory failure it has been shown to induce several effects beyond those expected for a standard oxygen therapy, such as increased carbon dioxide (CO2) clearance and positive airway pressure. One of the potential indications for HFNC is to facilitate weaning from mechanical ventilation and extubation. As weaning failure is one of the most complex challenges in mechanically ventilated patients, the use of HFNC after extubation, in order to prevent reintubation, has been evaluated in some clinical trials, with promising results. However, the role of HFNC postextubation is still controversial, and information regarding its effects on the pathophysiologic mechanisms of weaning failure is lacking. The goal of this proposal is to compare the acute physiologic effects of postextubation HFNC versus standard oxygen therapy, in critically ill patients, on relevant mechanisms related to weaning failure: work of breathing, lung function, systemic hemodynamics. This will be a randomized crossover study which will include critically ill mechanically ventilated patients, who fulfill criteria indicating they may be ready for weaning from mechanical ventilation, and in whom a spontaneous breathing trial (SBT) is planned to determine if they should be extubated. After checking eligibility and obtaining informed consent, patients will be monitored with an esophageal catheter (esophageal / gastric pressures to determine work of breathing, and electric activity of diaphragm to determine neuromechanical coupling), and a noninvasive ventilation monitor (electric impedance tomography to assess global and regional ventilation). Work of breathing, lung function, and systemic hemodynamics will be assessed during the SBT. Inclusion in the study will be confirmed only if they pass the SBT and are extubated. During the first 2 hours after extubation patients will undergo one hour of HFNC and one hour of standard oxygen therapy, with the crossover sequence being randomized previously at the time of inclusion, and with assessments repeated at the end of each treatment period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
26
High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
Hospital Clínico UC Christus
Santiago, Santiago Metropolitan, Chile
Pressure time-product (PTP) per minute (cmH2O x s/min)
PTPmin will be assessed through an esophageal Neurovent catheter.
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Delta end-expiratory lung index (EELI)
Delta EELI will be obtained from electric impedance tomography (EIT) and measured relative to the tidal volume.
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Brain natriuretic peptide (BNP) plasma levels
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Pressure time-product per breath (cmH2O x s)
PTP will be assessed through an esophageal Neurovent catheter.
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Peak electric activity of the diaphragm (EAdi)
EAdi will be measured in uV through a Neurovent catheter connected to a Servo-i ventilator
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Neuroventilatory efficiency
Vt / EAdi (ml / uV)
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Neuromechanical efficiency
Ratio of the (Paw-PEEP) divided by EAdi during inspiratory occlusion (cmH2O / uV)
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
Global inhomogeneity index
index derived from EIT and calculated from the sum of the impedance changes of each pixel with respect to its median (in absolute values), divided by the sum of the impedance values of each pixel
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
PaO2 / FiO2
Parameter of oxygen exchange calculated as the ratio of PaO2 / FiO2
Time frame: 60 minutes after starting high flow nasal cannula or standard oxygen therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.